Get started
Author

Sandeep H. Mashru

Observed names: S. Mashru, S.H. Mashru, Sandeep H Mashru, Sandeep Mashru
Institution: Kaiser Permanente
OpenAlex ID: A5021064276
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
2020 · Nicole M Kuderer, Toni K Choueiri, et al. · The Lancet · 1,726
PDF
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · James Chih-Hsin Yang, Dae Ho Lee, et al. · Journal of Clinical Oncology · 165
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
2022 · Julie Fu, Sonya A. Reid, et al. · JAMA Network Open · 66
PDF
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
2020 · Sarah B. Goldberg, Mary W. Redman, et al. · Journal of Clinical Oncology · 65
PDF
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
2022 · Ziad Bakouny, Chris Labaki, et al. · JAMA Oncology · 54
PDF
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT -Methylated Glioblastoma
2024 · Jann N. Sarkaria, Karla V. Ballman, et al. · JAMA Oncology · 36
Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly
2003 · Veena John, Sandeep Mashru, et al. · Drugs & Aging · 35
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
2020 · Maheen Abidi, David M. Aboulafia, et al. · Cancer Cell · 31
PDF
Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
2022 · Jann Nagina Sarkaria, Karla V. Ballman, et al. · Journal of Clinical Oncology · 16
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
2023 · Shuchi Gulati, Chih-Yuan Hsu, et al. · JAMA Oncology · 10
PDF
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States
2022 · Jessica E. Hawley, Tianyi Sun, et al. · JAMA Network Open · 10
PDF
OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403
2018 · S. Goldberg, M. Redman, et al. · Journal of Thoracic Oncology · 8
PDF
Amivantamab plus chemotherapy vs chemotherapy in EGFR -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.
2025 · Raffaele Califano, Antonio Passaro, et al. · Journal of Clinical Oncology · 7
PDF
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
2023 · Gayathri Nagaraj, Shaveta Vinayak, et al. · eLife · 3
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
2025 · Pascale Tomasini, Oscar Juan-Vidal, et al. · Clinical Lung Cancer · 2
S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
2025 · Sukhmani Kaur Padda, Mary Weber Redman, et al. · Journal of Clinical Oncology · 2
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
2023 · Douglas B. Johnson, Michael B. Atkins, et al. · BMC Cancer · 2
PDF
Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404.
2024 · Michael Brian LaPelusa, David Marcano, et al. · Journal of Clinical Oncology · 1
Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
2023 · Gayathri Nagaraj, Shaveta Vinayak, et al. · 1
PDF
705 Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40–002, trial in progress)
2022 · April Salama, Meredith McKean, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab
2026 · Marija Balic, Gong Tang, et al. · JCO Precision Oncology
PDF
COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium
2026 · Alaina J. Brown, Chih-Yuan Hsu, et al. · JCO oncology advances.
AI-Assisted Contour Quality Assurance for HN005 Clinical Trial
2025 · D. Wang, S.S. Yom, et al. · International Journal of Radiation Oncology*Biology*Physics
Works count: 23
Citation count: 2,241
H-index: 10
I10-index: 11
Year
Topic
Type